Celgene Corp. (CELG)

Operating Profit Margin
since 2005

Low level of difficulty

Celgene Corp., operating profit margin, long-term trends, calculation

	Operating profit margin	=	100	×	Operating income (loss)¹	÷	Net product sales¹
Dec 31, 2018	34.01%	=	100	×	5,191	÷	15,265
Dec 31, 2017	36.28%	=	100	×	4,707	÷	12,973
Dec 31, 2016	28.31%	=	100	×	3,167	÷	11,185
Dec 31, 2015	24.61%	=	100	×	2,255	÷	9,161
Dec 31, 2014	33.30%	=	100	×	2,519	÷	7,564
Dec 31, 2013	28.43%	=	100	×	1,809	÷	6,362
Dec 31, 2012	32.43%	=	100	×	1,746	÷	5,386
Dec 31, 2011	30.70%	=	100	×	1,443	÷	4,700
Dec 31, 2010	28.21%	=	100	×	990	÷	3,508
Dec 31, 2009	32.78%	=	100	×	842	÷	2,567
Dec 31, 2008	-68.50%	=	100	×	(1,464)	÷	2,138
Dec 31, 2007	32.69%	=	100	×	425	÷	1,300
Dec 31, 2006	21.52%	=	100	×	175	÷	812
Dec 31, 2005	18.76%	=	100	×	84	÷	446

¹ US$ in millions

Celgene Corp., operating profit margin, long-term trends, comparison to competitors

	Celgene Corp.	Abbott Laboratories	AbbVie Inc.	Allergan PLC	Amgen Inc.	Biogen Inc.	Gilead Sciences Inc.	Regeneron Pharmaceuticals Inc.
Dec 31, 2018	34.01%	11.94%	19.49%	-39.57%	45.55%	43.77%	37.83%	37.77%
Dec 31, 2017	36.28%	6.30%	33.99%	-37.15%	45.76%	43.54%	55.04%	35.41%
Dec 31, 2016	28.31%	15.27%	36.60%	-12.53%	44.74%	44.99%	58.87%	27.38%
Dec 31, 2015	24.61%	14.05%	32.97%	-20.00%	40.44%	45.44%	69.03%	30.51%
Dec 31, 2014	33.30%	12.84%	17.09%	-9.71%	32.03%	40.94%	62.37%	29.74%
Dec 31, 2013	28.43%	12.03%	30.14%	-4.88%	32.25%	36.29%	41.87%	36.11%
Dec 31, 2012	32.43%	20.28%	31.65%	5.42%	33.52%	33.64%	42.67%	33.20%
Dec 31, 2011	30.70%	14.81%	—	11.70%	28.19%	34.16%	46.77%	-46.02%
Dec 31, 2010	28.21%	17.31%	—	8.56%	37.82%	26.48%	53.62%	-21.23%
Dec 31, 2009	32.78%	20.27%	—	13.75%	38.37%	29.59%	54.55%	-19.54%
Dec 31, 2008	-68.50%	19.28%	—	14.12%	35.50%	29.62%	52.68%	-37.67%
Dec 31, 2007	32.69%	17.67%	—	10.24%	27.81%	24.59%	57.98%	-91.55%
Dec 31, 2006	21.52%	9.09%	—	-21.33%	27.71%	16.40%	-29.32%	-169.68%
Dec 31, 2005	18.76%	19.53%	—	13.27%	40.33%	9.74%	61.41%	-187.97%